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Introduction. Among nonantibiotic cough remedies, herbal preparations containing extracts from leaves of ivy (Hedera helix)
enjoy great popularity. Objective. A systematic review to assess the eﬀectiveness and tolerability of ivy for acute upper respiratory
tract infections (URTIs). Methods. We searched for randomized controlled trials (RCTs), nonrandomized controlled clinical trials
and observational studies evaluating the eﬃcacy of ivy preparations for acute URTIs. Study quality was assessed by the Jadad score
or the EPHPP tool. Results. 10 eligible studies were identiﬁed reporting on 17463 subjects. Studies were heterogeneous in design
and conduct; 2 were RCTs. Three studies evaluated a combination of ivy and thyme, 7 studies investigated monopreparations
of ivy. Only one RCT (n = 360) investigating an ivy/thyme combination used a placebo control and showed statistically
signiﬁcant superiority in reducing the frequency and duration of cough. All other studies lack a placebo control and show
serious methodological ﬂaws. They all conclude that ivy extracts are eﬀective for reducing symptoms of URTI. Conclusion.
Although all studies report that ivy extracts are eﬀective to reduce symptoms of URTI, there is no convincing evidence due to
serious methodological ﬂaws and lack of placebo controls. The combination of ivy and thyme might be more eﬀective but needs
conﬁrmation.
1.Introduction
Cough is a highly prevalent condition and a common reason
for consultations in general practice [1–4]. Most frequently,
cough symptoms are caused by acute viral upper respiratory
tract infections (URTIs) and the course is mostly benign and
self-limiting, although bacterial superinfection may occur in
acute bronchitis [5, 6]. For chronic cough, important causes
are chronic obstructive pulmonary disease (COPD) and
asthma which are characterized by airway obstruction and
hypersecretionofmucus,additionallycausingsymptomslike
wheezing or dyspnoea.
Inappropriate use of antibiotics for viral respiratory tract
infections is a signiﬁcant problem causing both pathogen
resistance and substantial health care expenditure without
aﬀectingtheresolutionofcough[7].Thereforenonantibiotic
alternative treatment options are needed. Commonly used
over-the-counter drugs for acute cough in both children
and adults are mucolytic agents and antitussives, which are
also widely prescribed in primary care settings [8]. In the
UK, cough liquids accounted for sales worth 102 million
pounds in 2008 [9]. Among these nonantibiotic cough
remedies, herbal preparations containing extracts from the
leaves of ivy (Hedera helix L.) enjoy great popularity in
many European countries [10–12]. In 2007, more than 80%
of herbal expectorants prescribed in Germany comprised
ivy extract and amounted to nearly 2 million prescriptions
nationwide and a volume of sales exceeding 13 million Euros
[10].
Ivy leaf contains saponins which are considered to have
mucolytic, spasmolytic, bronchodilatory and antibacterial
eﬀects [13, 14]. Despite widespread use of ivy leaf extracts,
the eﬀectiveness for the treatment of acute cough is not well
established. Methodically strong clinical studies seem scarce
despite the epidemiological and economic importance. To
our knowledge, there is no comprehensive systematic review2 Evidence-Based Complementary and Alternative Medicine
of the available clinical evidence. A Cochrane Review
assessingover-the-countercoughmedicationsdoesnotcover
herbal drugs [8]. Other reviews focus on eﬀectiveness of ivy
leaf extracts in asthma or COPD [12, 15–17]. Therefore,
we performed a systematic review of the eﬀectiveness and
tolerability of ivy preparations for the treatment of acute
URTIs in children and adults.
2. Methods
2.1. Data Sources. Our search included 3 electronic biblio-
graphic databases: MEDLINE, EMBASE and the Cochrane
Library. We included studies published from the respective
inception of the databases until 20. December 2009. There
was no language restriction. Search terms were: ivy, hed-
era, respiratory tract diseases, respirat∗,c o u g h ,b r o n c h i t i s ,
bronchial. The complete search algorithm with the keywords
and MeSH-terms used is available from the authors upon
request. Additionally, we hand searched the bibliographies
of the publications retrieved. Several manufacturer websites
were also scanned manually for references.
2.2. Study Selection
2.2.1. Eligibility Criteria. We did not exclude speciﬁc pop-
ulations or age groups. Our search included published
randomizedcontrolledtrials(RCTs),controlledclinicaltrials
(CCTs) and noncontrolled observational studies (OSs) eval-
uating the eﬀectiveness and/or tolerability of medications
containing ivy leaf extract for the treatment of acute URTIs
including bronchitis. Studies investigating patients with a
variety of other acute (e.g., pertussis, pneumonia) and
chronic diseases (COPD, asthma) were excluded. However,
we did not disregard studies where URTI patients repre-
sented the majority of investigated subjects or treatment
results were reported separately. Ivy leaf extract could be the
only ingredient in the respective drug preparation or could
be combined with other herbal components. We restricted
the search on studies evaluating oral or rectal administration
forms. Outcome measures could be hard clinical endpoints
(e.g., morbidity, mortality, health-related quality of life),
surrogate values like spirometric parameters, physician’s
ﬁndings upon clinical examination, assessment of symptoms
(e.g., cough) by either physician or patient, and undesirable
side eﬀects of treatment.
2.2.2. Screening Process. The titles and abstracts of the cita-
tions identiﬁed were screened by two independent reviewers
(FH and JFC) separately using a predesigned form. Titles
and abstracts that clearly did not meet the inclusion criteria
regarding indication (respiratory symptoms) or intervention
(drug containing ivy leaf extract) were excluded. Duplicate
titles were also eliminated. For publications fulﬁlling the
inclusion criteria or for which inclusion or exclusion could
not be ascertained, we reviewed the full text. Disagreements
were resolved by consensus. A list of references of excluded
studies is available upon request from the authors. Figure 1
shows a detailed outline of the study selection process.
2.3. Quality Assessment and Data Extraction. For quality
assessment of RCT, the Jadad scale (score 0−5) was used
[18]. The Jadad scale is not designed for assessment of
nonrandomized or noncontrolled studies as it covers mainly
the study characteristics of blinding and attrition [18, 19].
To assess the methodological quality of CCTs and OSs
we used the Quality Assessment Tool for Quantitative
Studies developed by the Eﬀective Public Health Practice
Project (EPHPP, McMaster University, Ontario, Canada)
[20, 21]. Based on several component ratings (selection
bias, study design, confounders, blinding, data collection
methods, withdrawals), studies are given a global rating
of either “strong”, “moderate” or “weak”. RCTs were given
both a Jadad score and an EPHPP rating. Data was then
extracted using a predesigned spreadsheet. These steps of
critical quality appraisal and data extraction were performed
independently by the two reviewers. Disagreements were
resolved by consensus.
2.4. Data Analysis. The included studies were categorized
according to their study design: RCT, CCT or OS. For
controlled studies, the following comparisons were made:
(1) ivy leaf extract versus placebo, (2) ivy leaf extract
versus conventional therapy, (3) comparison of diﬀerent
formulations of Ivy leaf extract. For OSs ﬁndings before and
after treatment are reported. Due to highly heterogeneous
outcomes used by the included studies, we did not attempt
to calculate pooled results.
3. Results
3.1. Characteristics of Included Studies. Our search identiﬁed
263 potentially relevant citations. Of these, 27 publications
were retrieved for evaluation of the full text. We retained
10 studies for inclusion into the review. The studies were
published between 1985 and 2009 and originated from a
variety of countries (Germany n = 5, Switzerland n =
2, Latin America n = 2, Ukraine n = 1). The studies
report on a total of 17463 subjects in treatment and control
groups. Three of these studies included only children, 2
studies only adults and 5 studies included both. Studies
were heterogeneous in design and conduct, 2 were RCT, one
was a CCT and 7 were OS. Of the 3 controlled studies,
only one was placebo-controlled [22], one compared ivy
leaf to a conventional expectorant (acetylcysteine) [23].
The third study compared two diﬀerent syrup formulations
containing ivy leaf extract [24]. Most studies investigated
mono-preparations of ivy leaf extract, but 3 studies tested a
mixture of ivy leaf and thyme extract [22, 25, 26]. One of
these used a randomized controlled design [22].
The studies included patients with cough due to URTIs
including acute bronchitis. Some studies included few
patients with chronic bronchitis [26, 27], or the authors
did not diﬀerentiate distinctly between acute disease and
acute exacerbations of chronic disease [27, 28]. One study
included COPD and pertussis patients, but reported the
results separately [29]. The outcomes assessed by the studies
were heterogeneous. Studies reported assessment of URTIEvidence-Based Complementary and Alternative Medicine 3
Duplicate citations
n = 14
Analysis of titles and
abstracts
Analysis of full
manuscripts
Exclusion
n = 17
Exclusion
n = 222
Articles retrieved in full-text
n = 27
Studies included in the review
n = 10
Animal experiments n = 1
No focus on URTI n =8
Secondary reporting of published results,
no own study conducted n = 1
R e p o r t i n go fr e t r o s p e c t i v ed a t a ,
no own study conducted n = 1
Narrative review n = 5
Article could not be obtained in full text n = 1
Reasons for exclusion of full-text articles:
Potentially relevant citations n = 263
From MEDLINE n = 149
From EMBASE n = 59
n = 17
From hand search n = 38
From Cochrane library
Figure 1: Study selection process.
symptoms by the treating physician or results of physical
examination. Symptoms assessed varied (e.g., urge to cough,
frequency of coughing, quality and quantity of sputum,
shortness of breath, auscultation results). Symptom severity
was measured by a variety of instruments. Two studies [22,
26] used the BSS (bronchitis severity score) scale. Several
studies mainly reported percentages of improvement or cure
of symptoms after a certain treatment period. Two studies
additionally reported a global self-assessment by patients
[25, 30]. One study measured and reported spirometric
parameters [23]. An overview of the characteristics of the
studies is given in Table 1.
Only one RCT met the standards of good clinical
practice with regard to conduct and reporting, sample size
calculation and an appropriate statistical analysis and was
rated with a Jadad score of 5 (“strong”) [22]. All other
studies, including the second RCT [24] had serious ﬂaws.
It was often impossible to discern whether the participants
were representative of the target population of unselected
URTI patients. The studies did not describe the selection
processorreliedonself-selectedparticipants(selectionbias).
Confounding was a problem in a large number of studies as
well. Many studies allowed concomitant use of other cough
remedies or even antibiotics or steroids [23, 29, 30] or did
not address this factor at all [26]. Presence of concomitant
diseases (e.g., cardiovascular) was not an exclusion criterion
[23, 25, 29] or not assessed [26, 30]. Dropout rates or
reasons for dropout were frequently not reported [27–
31]. No intention-to-treat analysis was reported. Statistical
analysis was performed by only few studies [22–24,27],most
studiesjustdescribetheresults.OnestudyreportingP-values
does not mention the statistical test performed [23]. Table 2
shows details of the quality assessment.
The reported results are shown in Table 3 and summa-
rized in the following sections.
3.2. Ivy Leaf Extract versus Placebo. No studies comparing
ivy leaf mono-preparations for the treatment of URTIs to
a placebo control could be identiﬁed. One German RCT4 Evidence-Based Complementary and Alternative Medicine
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Table 2: Quality assessment of included studies.
Reference
EPHPP Section ratings (strong/moderate/weak) Global
rating
Jadad
score(0−5) Selection
bias
Study
design Confounders Blinding Data
collection Withdrawals
Randomized controlled trials (RCTs)
Kemmerich
et al. 2006 moderate strong strong strong weak strong strong 5
Unkauf and
Friedrich
2000
weak strong moderate weak weak strong weak 2
Controlled trials (CCTs)
Bolbot et al.
2004 moderate moderate weak weak moderate strong weak n.a.
Observational studies (OSs)
B¨ uechi and
K¨ ahler 2003 weak moderate weak weak weak weak weak
B¨ uechi et al.
2005 weak moderate weak weak weak strong weak
Fazio et al.
2009 moderate moderate weak weak weak strong weak
Hecker 1999 weak moderate weak weak weak weak weak n.a.
Leskow 1985 weak moderate moderate weak weak weak weak
Marzian 2007 moderate moderate weak weak weak weak weak
Santoro
J´ unior 2005 moderate moderate moderate weak weak strong weak
n.a. = not applicable.
compared ivy/thyme to placebo [22]. This trial included
370 adult patients which were treated for 10 days with a
s yr u p( i v y1 . 5gl i q u i de x t ra c t / 1 0 0g1:1 ,e t h a n o l7 0 % ,t h ym e
15g liquid extract/100g 1 : 2−2.5). Outcome measures were
the frequency of coughing ﬁts, the time to a relative 50%
reduction in coughing ﬁts, the BSS and overall response
rate. All outcomes assessed were signiﬁcantly better in the
intervention group.
3.3. Ivy Leaf Extract versus Conventional Expectorant Therapy.
One Ukrainian study group conducted a CCT comparing
ivy to acetylcysteine in acute bronchitis [23]. A total of
50 children were treated for 7−10 days with either syrup
containing ivy leaf extract or 300−1200mg of acetylcys-
teine. Symptoms (cough, sputum, shortness of breath) were
improved in both groups after treatment. Compared to the
baseline, both treatment groups showed improved spiromet-
ric values (FVC, FEV1, PEF) after treatment. Spirometric
parameters were signiﬁcantly better in the group receiving
the ivy formulation. The authors conclude that ivy leaf has
b r o n c h o d i l a t o r ya sw e l la sm u c o l y t i ce ﬀects.
3.4. Comparison of Diﬀerent Formulations of Ivy. One of the
two RCTs included in this systematic review compared two
diﬀerent syrup preparations of ivy leaf extract (0.33−0.5g
dry extract/100ml 3−6:1, ethanol 60%, versus 0,7g dry
extract/100ml 5−7.5:1, ethanol 30%) [24]. A total of 52
patients were treated for 10 days after randomization,
severity of cough symptoms was assessed. No signiﬁcant
diﬀerence was observed.
3.5. Observational Studies. Five noncontrolled OSs investi-
gated ivy mono-preparations [27–31] and 2 OSs investigated
ivy/thyme combinations [25, 26]. These studies included
a large number of patients, the 2 largest studies (both
conducted in Latin America) [27, 31] together reporting
on over 15000 subjects. Most of the OSs were postmar-
keting surveillance-studies sponsored by the manufacturers.
Symptoms were assessed at baseline and after treatment
for 7 to 10 days, mostly by the investigating physicians.
Diﬀerent symptoms (e.g., cough, expectoration, shortness
of breath) were assessed on a variety of scales. Two studies
used a four-level Likert scale [28, 30]. Most studies observed
improvement or cure after treatment in more than 90%.
Global eﬃcacy was rated as good or very good by physicians
in 77−86% [25, 28, 30]. One study assessing auscultation
ﬁndings reported signiﬁcantly less rales after treatment
compared to baseline [27].
3.6. Adverse Events. All but one publication studied adverse
events as an outcome parameter [24]. Side eﬀects were
observed in 0% [30]t o3 . 8 %[ 22]. Symptoms were mostly
mild and transient abdominal discomfort, diarrhoea or
nausea. One study reported allergic reactions in 0.1% of
patients (10 cases in a large study population of over 10000
patients)[31].Inanotherstudyonepatientoutof248(0.4%)
who was concomitantly treated with paracetamol developed6 Evidence-Based Complementary and Alternative Medicine
Table 3: Summary of the results of included studies.
Reference Diagnosis
Treatment Outcomes assessed
(selection)∗
Results
Statistics∗∗
Intervention
group Control group Intervention group Control group
Ivy leaf extract versus placebo
Kemmerich
et al. 2006
Acute
bronchitis
Ivy +
Thyme
(syrup)
Placebo
Change in frequency
of coughing ﬁts
(relative reduction),
time to cessation of
ﬁts, Bronchitis
severity score (BSS),
Response to
treatment (AD)
Frequency of
coughing ﬁts ↓ 77.6%,
Frequency of
coughing ﬁts ↓ 55.9%, P<. 0001
Time to a 50%
r e d u c t i o ni nﬁ t s6 d ,
Time to a 50%
reduction in ﬁts 8d, P<. 0001
BSS ↓ (8.2 →1.6), BSS ↓ (8.3 →3.3), P<. 0001
Response rate 96.2% Response rate 74.7% P<. 0001
Ivy leaf extract versus conventional expectorant therapy
Bolbot et al.
2004
Acute
bronchitis Ivy (syrup) Acetylcysteine
FVC, FEV1, PEF,
Change in symptoms
cough frequency,
sputum, shortness of
breath, respiratory
pain, Global
assessment of eﬃcacy
(based on symptoms)
(AD)
FVC ↑ FVC ↑ s
FEV1 ↑ FEV1 ↑ s
PEF ↑ PEF ↑ s
Global eﬃcacy rated
as very good in 40.0%
Global eﬃcacy rated
as very good in 12.5% s
Comparison of diﬀerent formulations of ivy
Unkauf and
Friedrich
2000
Acute
bronchitis Ivy (syrup) Ivy (syrup)
Severity of bronchitis
assessed on visual
analogue scale (AD),
Frequency and quality
of cough
Severity ↓ (on scale ↓
67.3 mm)
Severity ↓ (on scale ↓
64.2mm)
P = .0031
for
equivalence
After treatment
26.9% without
bronchitis
After treatment
36.5% without
bronchitis
ns
Observational studies (OSs)
B¨ uechi and
K¨ ahler 2003
Acute
bronchitis,
common
cold
Ivy
(pastilles) n.a.
Change in symptoms
urge to cough and
sputum quantity on a
scale (1−4) (AD),
Global assessment of
eﬃcacy (AD, AP)
Urge to cough ↓
(2.7 → 1.3)
n.a. no statistics
Sputum quantity ↓
(1.5 →1.1)
Eﬃcacy rated as very
good or good in 78%
(AD) and 77% (AP)
B¨ uechi et al.
2005
Acute and
chronic
bronchitis,
common
cold
Ivy +
Thyme
(syrup)
n.a.
Change in symptoms
urge to cough,
sputum quantity,
sputum consistency,
ease of expectoration
on a scale (1−4),
Global assessment of
eﬃcacy (AD, AP)
Change of median
symptom score for
urge to cough,
sputum consistency
and ease of
expectoration 3 → 1,
for sputum quantity
2 → 1, Eﬃcacy rated
as very good or good
in 86% (AD) and
90% (AP)
n.a. no statistics
Fazio et al.
2009
Acute and
chronic
bronchitis,
cough
Ivy (syrup) n.a.
Change in symptoms
cough, expectoration,
shortness of breath,
respiratory pain (AD)
Improvement or cure
for cough in 93.4%,
expectoration 92.9%,
shortness of breath
91.2%, pain 90.8%
n.a. no statisticsEvidence-Based Complementary and Alternative Medicine 7
Table 3: Continued.
Reference Diagnosis
Treatment Outcomes assessed
(selection)∗
Results
Statistics∗∗
Intervention
group Control group Intervention group Control group
Hecker 1999 Bronchitis Ivy (syrup) n.a.
Change in symptoms
cough, expectoration,
shortness of breath,
respiratory pain on a
scale (1−4) (AD),
Global assessment of
eﬃcacy (AD)
Improvement or cure
for cough in 91.3%,
expectoration 87.5%,
shortness of breath
57.7%, pain 60.9%,
Eﬃcacy rated as very
good or good in 86%
n.a. no statistics
Leskow 1985
Acute and
chronic
bronchitis,
chesty
cough,
pertussis
Ivy (drops) n.a.
Change in symptoms
cough, expectoration,
shortness of breath
(AD)
Improvement or cure
for cough in 96.4%,
expectoration 100%,
shortness of breath
100%
n.a. no statistics
Marzian
2007
Acute
bronchitis
Ivy+Thyme
(syrup) n.a.
Change in frequency
of coughing ﬁts,
Bronchitis severity
score
(BSS),Improvement
yes/no (AD)
Coughing ﬁts ↓
(25.1/d → 4.7/d),
BSS ↓ (8.9 → 1.2),
Improvement or cure
in 94%
n.a. no statistics
Santoro
J´ unior 2005 Bronchitis Ivy (syrup) n.a.
Change in symptoms
cough and shortness
of breath,
Auscultation results
(AD)
Cough ↓ (98.8% →
5.4% of patients),
shortness of breath ↓
Auscultation: rales ↓
n.a. s
n.a. = not applicable, ns = not statistically signiﬁcant, s = statistically signiﬁcant, FVC = forced vital capacity, PEF = peak expiratory ﬂow, FEV1 = forced
expiratory volume in one second, AD = assessment by doctor, AP = assessment by patient, ∗only outcome parameters reported in a manner allowing
comparison between groups are listed (RCT/CCT), for OS: selected relevant outcomes. ∗∗if reported: P-value for intervention compared to control. For OS:
P-value for baseline compared to after treatment.
an allergic skin rash [28]. Severe or fatal adverse events
were not reported. In the RCT comparing an ivy/thyme
preparation to placebo [22], rates for frequency of observed
side eﬀects were similar in the treatment (3.8%) and placebo
(4.5%) group.
4. Discussion
4.1. Eﬀectiveness. All studies reviewed concluded that ivy leaf
extract is eﬀective for the treatment of URTIs. After 7 to
10 days of treatment, symptoms like cough or expectoration
are improved or cured in a large majority of patients. It has
to be noted that only one placebo-controlled RCT could be
retrieved. This trial showed superior results as to symptom
relief and speed of recovery in the intervention group treated
with a combination drug of ivy and thyme extract [22].
For ivy mono-preparations, sound evidence remains
scarce. All studies investigating a mono-preparation of ivy
extract lacked a placebo control. Only one study with
severe methodological ﬂaws compared ivy to acetylcysteine
[23]. The remaining observational studies all observed an
improvement of URTI symptoms in the course of treat-
ment. Although the authors of these studies claim to have
established eﬀectiveness, this conclusions are not warranted
since the natural course of URTIs is usually benign and self-
limiting. Uncomplicated acute bronchitis usually presents
with a phase of variable constitutional symptoms that
lasts for one to ﬁve days, followed by cough and phlegm
production lasting for one to 3 weeks, whereas cough lasting
f o rm o r et h a n2 1d a y sc a nb ed e ﬁ n e da ss u b a c u t eo rc h r o n i c
and requires further diagnostic workup [32]. A review of
the regression of symptoms in children with acute cough
observed that after 5 to 8 days, symptoms were improved
or gone in 50−75% of patients or patients were assessed as
recovered by their physicians [33]. After one week, cough
was resolved in about 50%. Improvement rates shown in the
Hederahelixstudiesincludedinthisreviewtendtobehigher,
often exceeding 90% [28, 29, 31]. However, these recovery
rates can not serve as direct comparison because many
other confounders (comedication, comorbidity) aﬀecting
the outcome have to be considered. Therefore, studies using
placebo controls are indispensable to establish eﬀectiveness.
Only for the combination of ivy and thyme evidence
for eﬀectiveness of faster recovery could be found [22].
A 50% reduction in coughing ﬁts was reached 2 days
earlier in the treatment group, which can be considered a
clinically relevant improvement. It remains unclear if the
observed eﬀect can be attributed to the action of thyme or
the combination. Although thyme is traditionally used for8 Evidence-Based Complementary and Alternative Medicine
URTIs, we found no clinical trials or a systematic review
evaluating the eﬀectiveness of mono-preparations of thyme.
Blinding might have been a problem since the producing
placebos with comparable taste and smell for oral herbal
therapies is diﬃcult.
4.2. Tolerability. The beneﬁts of any treatment have to be
weighted against potential harms. As severe adverse events
were not reported with more than 17000 subjects treated,
there is considerable evidence for the safety of hedera helix.
In the placebo-controlled study, only minimal diﬀerences
in adverse events between verum and placebo group were
observed [22]. Allergic reactions were reported in under
0.5% of cases with no cases of severe anaphylaxis mentioned
in any study. This is especially important regarding the fact
that hedera helix has been reported to cause allergic contact
dermatitis [34, 35] and rarely even occupational asthma in
gardeners exposed to the leaves [36].
4.3.StrengthsandLimitations. Wecomprehensivelysearched
medical databases with no restrictions regarding time or
language.Anextensivehand-searchingprocessaddedfurther
studies for review, so we can be conﬁdent as to the complete-
ness of the evidence identiﬁed. However, several limitations
have to be taken into account. Firstly, the databases covered
mainly focus on the American and European literature. As
hedera helix products are also marketed in the Middle East
and East Asia, some studies published in local journals
and not listed in MEDLINE or EMBASE could have been
missed. Furthermore, a large number of included studies was
sponsored by the manufacturers [22, 25–29, 31] or funding
was not reported. Studies sponsored by the manufacturer are
prone to publication bias [37]. One study was published in
a section of a phytotherapy journal in which articles origi-
nating from pharmaceutical companies could be published
without any editing or review [29].
A quantitative synthesis of the data gathered from
the studies (e.g., meta-analysis) was not possible due to
low-quality data and great heterogeneity in study designs
and outcomes. Future trials will require a consensus on a
standard for measuring symptom relief in URTIs.
5. Conclusion
Although many studies conclude that ivy extracts are
eﬀective to reduce symptoms of acute URTIs, their eﬀec-
tiveness is not established beyond reasonable doubt. The
studies reviewed show serious methodological ﬂaws and
lack placebo controls. Therefore their ﬁndings must be
interpreted with due caution. For a combination of ivy and
thyme, eﬀectiveness has been demonstrated in one RCT,
however these ﬁndings need to be conﬁrmed. Ivy extracts
are well tolerated, no serious adverse events were reported.
It has to be taken into account that other popular cough
medications, for example, acetylcysteine [38] and other OTC
antitussivesanddecongestants[8],alsolackasoundevidence
base. Reducing the use of antibiotics for uncomplicated
URTIs is an important public health goal [39]. Given a high
desire for treatment, abandoning the use of non-evidence-
basedcoughremediesmightcauseasurgeintheprescription
of antibiotics, which poses the risks of serious adverse events
and the development of antibiotic resistance. Considering
the popularity of ivy preparations and the considerable
expenditure for such remedies, further rigorously designed
randomized controlled trials are necessary.
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